$1.77 Million in Sales Expected for AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) This Quarter

Share on StockTwits

Wall Street analysts forecast that AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) will report sales of $1.77 million for the current fiscal quarter, Zacks reports. Two analysts have made estimates for AVEO Pharmaceuticals’ earnings. The lowest sales estimate is $450,000.00 and the highest is $3.08 million. AVEO Pharmaceuticals posted sales of $430,000.00 in the same quarter last year, which would indicate a positive year-over-year growth rate of 311.6%. The firm is expected to report its next quarterly earnings results on Tuesday, August 6th.

On average, analysts expect that AVEO Pharmaceuticals will report full year sales of $11.05 million for the current year, with estimates ranging from $3.11 million to $24.30 million. For the next fiscal year, analysts forecast that the business will post sales of $18.18 million, with estimates ranging from $3.60 million to $30.60 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow AVEO Pharmaceuticals.

AVEO Pharmaceuticals (NASDAQ:AVEO) last announced its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The firm had revenue of $1.61 million during the quarter, compared to analysts’ expectations of $0.74 million. AVEO Pharmaceuticals had a net margin of 70.30% and a negative return on equity of 24.50%.

A number of analysts have issued reports on the company. National Securities reaffirmed a “sell” rating and issued a $5.00 target price on shares of Oxford Square Capital in a research note on Thursday, March 28th. Zacks Investment Research downgraded HEXO from a “hold” rating to a “sell” rating in a research note on Wednesday, May 15th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $1.96.

AVEO stock traded down $0.01 during midday trading on Friday, reaching $0.71. The stock had a trading volume of 1,925,446 shares, compared to its average volume of 5,085,601. The firm has a fifty day moving average price of $0.72. The stock has a market cap of $115.89 million, a P/E ratio of -3.74 and a beta of 0.88. AVEO Pharmaceuticals has a 52-week low of $0.49 and a 52-week high of $3.59.

Several institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. increased its stake in shares of AVEO Pharmaceuticals by 3.3% in the 4th quarter. BlackRock Inc. now owns 7,357,716 shares of the biopharmaceutical company’s stock worth $11,773,000 after acquiring an additional 236,822 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of AVEO Pharmaceuticals by 36.3% in the 4th quarter. Geode Capital Management LLC now owns 1,394,576 shares of the biopharmaceutical company’s stock worth $2,231,000 after acquiring an additional 371,327 shares during the last quarter. Northern Trust Corp increased its stake in shares of AVEO Pharmaceuticals by 3.0% in the 4th quarter. Northern Trust Corp now owns 1,175,604 shares of the biopharmaceutical company’s stock worth $1,882,000 after acquiring an additional 34,164 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of AVEO Pharmaceuticals by 28.0% in the 4th quarter. Bank of New York Mellon Corp now owns 423,673 shares of the biopharmaceutical company’s stock worth $678,000 after acquiring an additional 92,663 shares during the last quarter. Finally, Two Sigma Advisers LP increased its position in shares of AVEO Pharmaceuticals by 7.2% during the 4th quarter. Two Sigma Advisers LP now owns 422,000 shares of the biopharmaceutical company’s stock worth $675,000 after purchasing an additional 28,500 shares during the last quarter. 28.33% of the stock is owned by institutional investors and hedge funds.

AVEO Pharmaceuticals Company Profile

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).

Further Reading: Percentage Decliners

Get a free copy of the Zacks research report on AVEO Pharmaceuticals (AVEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AVEO Pharmaceuticals (NASDAQ:AVEO)

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.